These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6851401)

  • 1. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979.
    May MS; Wardell WM; Lasagna L
    Clin Pharmacol Ther; 1983 Jun; 33(6):691-700. PubMed ID: 6851401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research activity on systemic contraceptive drugs by the U.S. pharmaceutical industry, 1963-1976.
    DiRaddo J; Wardell WM
    Contraception; 1981 Apr; 23(4):345-65. PubMed ID: 7273757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of self-originated new drugs by Swiss pharmaceutical firms, 1960-1980.
    Mattison N; Thomas E; Trimble AG; Wardell WM
    Regul Toxicol Pharmacol; 1984 Jun; 4(2):157-73. PubMed ID: 6377400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new drug approvals of 1987, 1988, and 1989: trends in drug development.
    Kaitin KI; DiCerbo PA; Lasagna L
    J Clin Pharmacol; 1991 Feb; 31(2):116-22. PubMed ID: 2010558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980).
    Prentis RA; Walker SR
    Br J Clin Pharmacol; 1986 Apr; 21(4):437-43. PubMed ID: 3518774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976.
    Wardell WM; DiRaddo J; Trimble AG
    Clin Pharmacol Ther; 1980 Aug; 28(2):270-7. PubMed ID: 7398194
    [No Abstract]   [Full Text] [Related]  

  • 14. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug development in the United States, 1963 through 1984.
    Mattison N; Trimble AG; Lasagna L
    Clin Pharmacol Ther; 1988 Mar; 43(3):290-301. PubMed ID: 3278822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why trash don't pass? pharmaceutical licensing and safety performance of drugs.
    Banerjee T; Nayak A
    Eur J Health Econ; 2017 Jan; 18(1):59-71. PubMed ID: 26781296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs.
    Kaitin KI; Phelan NR; Raiford D; Morris B
    J Clin Pharmacol; 1991 Jan; 31(1):17-24. PubMed ID: 2045524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New indications for already-approved drugs: an analysis of regulatory review times.
    DiMasi JA; Kaitin KI; Fernandez-Carol C; Lasagna L
    J Clin Pharmacol; 1991 Mar; 31(3):205-15. PubMed ID: 2019661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug applications: how long to gain approval?
    Spivey RN; Lasagna L; Trimble AG
    Clin Pharmacol Ther; 1985 Apr; 37(4):361-6. PubMed ID: 3978995
    [No Abstract]   [Full Text] [Related]  

  • 20. Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?
    Gauvin DV; Zimmermann ZJ; Kallman MJ
    Drug Alcohol Depend; 2016 Nov; 168():307-319. PubMed ID: 27629024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.